Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLAG Chemotherapy + Lisaftoclax + Pelcitoclax in R/R T-ALL
NCT07428486Phase 1Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2026
- Primary completion
- Apr 2026
- Modality
- Orthosteric Ligands
01
Overview
Phase 1, open-label, single-arm trial of lisaftoclax and pelcitoclax in t-cell acute lymphoblastic leukemia (T-ALL), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Safety and adverse events at 1 year. Planned start Apr 2026; status: withdrawn.
02
Drugs
lisaftoclaxpelcitoclax
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)
Beyond the preview
Go deeper on NCT07428486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07428486.